NCT05088889 - Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions

Stage IV Pancreatic Cancer

Interventions

DRUG

Nivolumab

Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks

DRUG

ipilimumab

Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks

RADIATION

Stereotactic body radiation therapy

Three fractions of 8 Gy, treated on alternate days

RADIATION

Low dose irradiation

a single fraction of 2Gy will be given to the metastatic lesions at first progression

Trial Locations (1)

RECRUITING

Sheba Medical Centre, Ramat Gan